non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Radiotherapy

Indolent Stage I/Contiguous Stage II NHL
  • Studies suggest doses of 25-40 Gy
  • May be given as local or extended-field RT
Aggressive Stage I/Contiguous Stage II NHL
  • Involved site radiation therapy (ISRT) may be given with or without chemotherapy (usually R-CHOP)
    • Studies have shown an increase in the overall survival & event-free survival rates of patients given CHOP with involved-site radiation therapy (ISRT)
Indolent Noncontiguous Stage II/III/IV NHL
  • Studies suggest doses of 25-40 Gy
  • Total body irradiation (TBI), EF-XRT, & TBI followed by high-dose radioimmunotherapy are still under clinical evaluation & needs further studies to prove efficacy in patients with indolent noncontiguous stage II/III/IV NHL
Aggressive Noncontiguous Stage II/III/IV NHL
  • Local-field XRT is recommended with combination chemotherapy
Recurrent NHL
  • Low dose involved site radiation therapy (ISRT) is recommended to indolent/aggressive relapsed NHL patients for palliative purposes
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.